Optimizing the Efficacy of First-Line Chemotherapy plus Bevacizumab in Metastatic Colorectal Cancer: Analysis of Multiple Methods

Author： Li Shaotang

Publisher： Adis International

ISSN： 1173-8804

Source： BioDrugs, Vol.25, Iss.1, 2011-02, pp. : 43-50

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Spotlight on Bevacizumab in Metastatic Colorectal Cancer

By McCormack Paul L. Keam Susan J.

BioDrugs, Vol. 22, Iss. 5, 2008-01 ,pp. : 339-341

Adis International

Access to resources Recommend Favorite

Bevacizumab: In First-Line Treatment of Advanced and/or Metastatic Renal Cell Carcinoma

By Frampton James E. Keating Gillian M.

BioDrugs, Vol. 22, Iss. 2, 2008-01 ,pp. : 113-120

Adis International

Access to resources Recommend Favorite

Bevacizumab Plus Platinum-Based Chemotherapy: In Advanced Non-Small Cell Lung Cancer

By Wagstaff Antona J. Keam Susan J. McCormack Paul L.

BioDrugs, Vol. 23, Iss. 3, 2009-06 ,pp. : 187-196

Adis International

Access to resources Recommend Favorite

Spotlight on Panitumumab in Metastatic Colorectal Cancer†

By Keating Gillian M.

BioDrugs, Vol. 24, Iss. 4, 2010-08 ,pp. : 275-278

Adis International

Access to resources Recommend Favorite

Planning for subgroup analysis: a case study of treatment-marker interaction in metastatic colorectal cancer

By Gonen M.

Controlled Clinical Trials, Vol. 24, Iss. 4, 2003-08 ,pp. : 355-363

Elsevier

Access to resources Recommend Favorite